HomeBIIB • NASDAQ
add
Biogen Inc
Previous close
$149.33
Day range
$148.51 - $153.68
Year range
$110.04 - $179.20
Market cap
22.51B USD
Avg Volume
1.72M
P/E ratio
13.99
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 2.53B | 2.79% |
Operating expense | 1.25B | -1.34% |
Net income | 466.50M | 20.08% |
Net profit margin | 18.40 | 16.75% |
Earnings per share | 4.81 | 17.89% |
EBITDA | 980.80M | 23.54% |
Effective tax rate | 16.29% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.96B | 133.07% |
Total assets | 29.21B | 3.16% |
Total liabilities | 11.00B | -7.98% |
Total equity | 18.21B | — |
Shares outstanding | 146.70M | — |
Price to book | 1.20 | — |
Return on assets | 6.77% | — |
Return on capital | 7.94% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 466.50M | 20.08% |
Cash from operations | 1.27B | 36.01% |
Cash from investing | -35.10M | 97.03% |
Cash from financing | -130.20M | -1,872.73% |
Net change in cash | 1.10B | 626.47% |
Free cash flow | 1.01B | -12.12% |
About
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Founded
1978
Headquarters
Website
Employees
7,605
